What is the 13F Pro Quality Score for BCPC?

13F Pro ranks BALCHEM CORP (BCPC) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BCPC's current score at https://13fpro.ai/research/BCPC (free sign-up required for the full ranking).

Where does 13F Pro source BCPC data?

All BALCHEM CORP fundamentals and ownership data come directly from SEC EDGAR. BALCHEM CORP files with the SEC under CIK 9326. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BCPC in?

BALCHEM CORP (BCPC) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is BCPC research updated on 13F Pro?

BCPC's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

BALCHEM CORP(BCPC)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 9326 BCPC stock profile & AI dashboard →

13F Pro Quality Score

65.9/100

Rank #552 of 2,879 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

53.8/100

Profitability

79.6/100

Balance Sheet

85.3/100

Earnings Quality

67.0/100

Free Cash Flow

76.3/100

Institutional Flow

39.6/100

Revenue Scale

50.3/100

Dilution Risk

43.5/100

BCPC Stock Analysis & AI Quality Score

AI stock analysis and institutional research for BALCHEM CORP (BCPC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BCPC at 65.9/100 on a 32-signal composite quality model, placing it at rank #552 of 2,879 stocks — the top 25% of the AI-ranked universe. BCPC scores in the top quartile across balance sheet strength (85.3), profitability (79.6), free cash flow (76.3). Areas of concern include institutional flow (39.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 43.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), BALCHEM CORP reports quarterly revenue of $270.7M, net income of $40.3M, an operating margin of 20.5%. Top institutional holders of BCPC by reported 13-F value include BlackRock,, VANGUARD PORTFOLIO MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. BCPC trades on the Nasdaq exchange and files with the SEC under CIK 9326. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BCPC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BALCHEM CORP directly from SEC EDGAR. BALCHEM CORP's 13F Pro composite quality score has ranged between 8 and 71 since 2021, currently 65.9 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about BALCHEM CORP

Quirks, history, and lore behind BCPC — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. specialty chemicals company · listed on Nasdaq · serves the human nutrition, animal health, and industrial markets · headquartered in New Jersey.
2
The Numbers
Annual revenue in the range of $800 million to $900 million — not a giant, but a small-cap compounder with consistently strong margins that Wall Street quietly loves.
3
The History
Founded in the 1960s, it built its early business around a deceptively simple technology: encapsulating sensitive ingredients so they survive processing and deliver where they're needed.
4
The Secret
Its core trick is microencapsulation — coating nutrients, minerals, or chemicals in a protective shell so they don't react, degrade, or smell bad before reaching their target.
5
The Lore
It is one of the world's leading producers of choline — a nutrient most people have never heard of but that goes into baby formula, animal feed, and dietary supplements globally.
6
The Giveaway
Ticker BCPC, this Balchem-sounding outfit has quietly encapsulated its way to decades of steady growth — one tiny coated particle at a time.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$270.7M

Net Income

Q1 2026

$40.3M

Free Cash Flow

Q1 2026

$40.1M

Operating Margin

Q1 2026

20.5%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+8.8% YoY

$1.04BFY 2025

FY21 $799.0MFY23 $922.4MFY24 $953.7MFY25 $1.04B

Net Income

+20.5% YoY

$154.8MFY 2025

FY21 $96.1MFY23 $108.5MFY24 $128.5MFY25 $154.8M

Operating Income

+14.4% YoY

$209.3MFY 2025

FY21 $127.5MFY23 $159.2MFY24 $182.9MFY25 $209.3M

EPS (Diluted)

+20.9% YoY

$4.75FY 2025

FY21 $2.94FY23 $3.35FY24 $3.93FY25 $4.75

Total Assets

+7.0% YoY

$1.69BFY 2025

FY21 $1.20BFY23 $1.60BFY24 $1.58BFY25 $1.69B

Total Debt

—FY 2025

FY21 —FY23 —FY24 —FY25 —

Op. Cash Flow

+19.0% YoY

$216.6MFY 2025

FY21 $160.5MFY23 $183.8MFY24 $182.0MFY25 $216.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2019	FY 2017
Revenue	$1.04B +8.8%	$953.7M +3.4%	$922.4M +15.4%	$799.0M +24.1%	$643.7M +8.2%	$594.8M
Net Income	$154.8M +20.5%	$128.5M +18.4%	$108.5M +12.9%	$96.1M +20.6%	$79.7M -11.5%	$90.1M
Operating Income	$209.3M +14.4%	$182.9M +14.9%	$159.2M +24.9%	$127.5M +24.3%	$102.6M +5.8%	$96.9M
EPS (Diluted)	$4.75 +20.9%	$3.93 +17.3%	$3.35 +13.9%	$2.94 +20.0%	$2.45 -12.2%	$2.79
Total Assets	$1.69B +7.0%	$1.58B -1.4%	$1.60B +33.2%	$1.20B +3.8%	$1.16B +19.9%	$963.6M
Total Debt	—	—	—	—	$2.5M -98.9%	$219.0M
Operating Cash Flow	$216.6M +19.0%	$182.0M -1.0%	$183.8M +14.5%	$160.5M +29.0%	$124.5M +12.5%	$110.6M

AI Insight: BCPC Financial Trends

Balchem delivered steady growth with revenue rising from $234M in Q2 2024 to $271M in Q1 2026, though operating cash flow remains volatile.

• Revenue grew 16% from $234M in Q2 2024 to $271M in Q1 2026, showing consistent quarterly progression.

• Operating income expanded from $46M in Q2 2024 to $56M in Q1 2026, reflecting improving operational performance.

• Net income increased from $32M in Q2 2024 to $40M in Q1 2026, demonstrating solid bottom-line growth.

• Equity strengthened from $1,112M in Q2 2024 to $1,285M in Q1 2026, indicating strong balance sheet growth.

⚠ Operating cash flow dropped sharply from $67M in Q4 2025 to $40M in Q1 2026, showing continued volatility.

⚠ Revenue declined sequentially from $268M in Q3 2025 to $264M in Q4 2025, breaking growth momentum.

AI Insight: BCPC Ratio Trends

BCPC's operating margin shows stability around 20% with ROIC gradually strengthening to 17.3% in Q1 2026.

• Operating margin remained stable between 19.6% and 20.5% across all quarters from Q2 2024 to Q1 2026.

• ROIC improved from 16.3% in Q3 2024 to 17.3% in Q1 2026, reaching its highest level.

• Net profit margin stayed consistently above 13.7%, ranging between 14.0% and 15.1% throughout the period.

⚠ ROA peaked at 9.7% in Q3 2025 before moderating to 9.5% in Q1 2026.

Get alerted when BCPC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for BALCHEM CORP including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BCPC

BlackRock, Inc.
$820.6M4,841,597 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$371.7M2,193,417 sh
VANGUARD CAPITAL MANAGEMENT LLC
$242.7M1,432,088 sh
WASATCH ADVISORS LP
$241.2M1,423,424 sh
Conestoga Capital Advisors, LLC
$212.1M1,251,189 sh
STATE STREET CORP
$210.3M1,240,736 sh
GEODE CAPITAL MANAGEMENT, LLC
$177.5M1,047,199 sh
MORGAN STANLEY
$145.3M857,369 sh
GENEVA CAPITAL MANAGEMENT LLC
$143.5M846,495 sh
FMR LLC
$101.5M598,670 sh

Fund	Value	Shares
BlackRock, Inc.	$820.6M	4,841,597
VANGUARD PORTFOLIO MANAGEMENT LLC	$371.7M	2,193,417
VANGUARD CAPITAL MANAGEMENT LLC	$242.7M	1,432,088
WASATCH ADVISORS LP	$241.2M	1,423,424
Conestoga Capital Advisors, LLC	$212.1M	1,251,189
STATE STREET CORP	$210.3M	1,240,736
GEODE CAPITAL MANAGEMENT, LLC	$177.5M	1,047,199
MORGAN STANLEY	$145.3M	857,369
GENEVA CAPITAL MANAGEMENT LLC	$143.5M	846,495
FMR LLC	$101.5M	598,670

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BCPC on your watchlist

Track score changes the day BALCHEM CORP files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BCPC a good stock to buy?

13F Pro's AI-powered analysis of BALCHEM CORP (BCPC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BCPC are available on the BCPC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own BCPC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BCPC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of BALCHEM CORP's investment landscape.